Arcturus Therapeutics Holdings Capital Raise of $50M
Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.
Value
$50M
Counterparty
Meiji Seika Pharma Co., Ltd.
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
Arcturus Therapeutics reported a decrease in total assets from $271.1 million at the end of 2025 to $215.3 million as of September 30, 2026, primarily driven by a reduction in cash and cash equivalents. The company's forward-looking statements highlight the termination of the CSL Collaboration Agreement and plans to advance its therapeutics pipeline, including ARCT-810 and ARCT-032, independently or with other partners.
Arcturus Therapeutics reported Q3 2026 financial results, ending the period with $281.3 million in cash and equivalents. The company highlighted pipeline progress, including the completion of the myNEO acquisition and plans to complete enrollment for its ARCT-032 Phase 2 cystic fibrosis study by year-end 2026.
Term
Q3 2026
“The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-generation mRNA delivery platform, which demonstrated a 38-fold improvement over the key lipid in ARCT-810 in non-human primates.”